source
- Eli Lilly inks $3.35 B China partnership as Immunovant halts lupus drug trialEli Lilly announced a new alliance with Beijing‑based InnoCare Pharma that could be worth up to $3.35 billion. The deal includes an upfront payment of $100 million and up to five target programs fo…
- Merck's $1.3B EyeBio investment yields first ophthalmology successMerck's strategic move to re-enter ophthalmology has begun to show results after its 2024 acquisition of EyeBio. The company committed $1.3 billion upfront for EyeBio, aiming to broaden its pipeli…